Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jun 23;7:4112. doi: 10.1038/s41598-017-04384-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

p65-mediated asporin promoter activity directly in human nucleus pulposus cells. (a) Asporin promoter activity detected by dual-luciferase reporter gene assay system in the presence of different doses of p65 and/or IL-1β. (b) Asporin promoter activity detected by dual-luciferase reporter gene assay system in the presence of different doses of p65/Bay 11 and/or 10 ng/ml IL-1β. (c) The specific sequences of the two putative p65 binding sites on the asporin promoter. (d) The schematic of the wild-type and mutant human asporin promoter constructs. (e and f) Asporin promoter activity induced by different doses of p65 and/or 10 ng/ml IL-1β with or without putative p65 binding sites mutation on asporin promoter. *P < 0.05, ***P < 0.001. P values were analyzed by one-way ANOVA. All data are representative of three independent experiments and are means ± SEM.

HHS Vulnerability Disclosure